- Home
- SGC vs AQST Comparison
SGC vs AQST Comparison
Compare SGC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- AQST
- Stock Information
- Founded
- SGC 1920
- AQST 2004
- Country
- SGC United States
- AQST United States
- Employees
- SGC N/A
- AQST N/A
- Industry
- SGC Apparel
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- AQST Health Care
- Exchange
- SGC Nasdaq
- AQST Nasdaq
- Market Cap
- SGC 215.7M
- AQST 809.3M
- IPO Year
- SGC N/A
- AQST 2018
- Fundamental
- Price
- SGC $9.02
- AQST $6.14
- Analyst Decision
- SGC Strong Buy
- AQST Strong Buy
- Analyst Count
- SGC 3
- AQST 6
- Target Price
- SGC $17.33
- AQST $10.33
- AVG Volume (30 Days)
- SGC 38.6K
- AQST 2.9M
- Earning Date
- SGC 11-03-2025
- AQST 11-05-2025
- Dividend Yield
- SGC 6.26%
- AQST N/A
- EPS Growth
- SGC N/A
- AQST N/A
- EPS
- SGC 0.36
- AQST N/A
- Revenue
- SGC $565,017,000.00
- AQST $43,397,000.00
- Revenue This Year
- SGC $1.63
- AQST N/A
- Revenue Next Year
- SGC $3.28
- AQST $51.39
- P/E Ratio
- SGC $24.79
- AQST N/A
- Revenue Growth
- SGC N/A
- AQST N/A
- 52 Week Low
- SGC $8.79
- AQST $2.12
- 52 Week High
- SGC $18.48
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- SGC 33.39
- AQST 45.82
- Support Level
- SGC $8.79
- AQST $5.84
- Resistance Level
- SGC $9.87
- AQST $6.93
- Average True Range (ATR)
- SGC 0.50
- AQST 0.40
- MACD
- SGC -0.04
- AQST -0.17
- Stochastic Oscillator
- SGC 13.97
- AQST 16.67
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.